全文获取类型
收费全文 | 424篇 |
免费 | 29篇 |
国内免费 | 6篇 |
专业分类
儿科学 | 30篇 |
妇产科学 | 4篇 |
基础医学 | 22篇 |
口腔科学 | 7篇 |
临床医学 | 49篇 |
内科学 | 88篇 |
皮肤病学 | 13篇 |
神经病学 | 11篇 |
特种医学 | 70篇 |
外科学 | 47篇 |
综合类 | 20篇 |
预防医学 | 36篇 |
眼科学 | 15篇 |
药学 | 11篇 |
中国医学 | 1篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 7篇 |
2020年 | 12篇 |
2019年 | 9篇 |
2018年 | 8篇 |
2017年 | 8篇 |
2016年 | 10篇 |
2015年 | 6篇 |
2014年 | 18篇 |
2013年 | 14篇 |
2012年 | 10篇 |
2011年 | 13篇 |
2010年 | 16篇 |
2009年 | 26篇 |
2008年 | 15篇 |
2007年 | 11篇 |
2006年 | 8篇 |
2005年 | 7篇 |
2004年 | 5篇 |
2003年 | 12篇 |
2002年 | 7篇 |
2001年 | 8篇 |
2000年 | 10篇 |
1999年 | 7篇 |
1998年 | 17篇 |
1997年 | 11篇 |
1996年 | 19篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 18篇 |
1992年 | 7篇 |
1991年 | 3篇 |
1990年 | 8篇 |
1989年 | 8篇 |
1988年 | 17篇 |
1987年 | 14篇 |
1986年 | 9篇 |
1985年 | 12篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1977年 | 3篇 |
1975年 | 4篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1970年 | 1篇 |
排序方式: 共有459条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
青蒿琥酯皮肤擦剂在小鼠和兔体内的药代动力学研究 总被引:1,自引:0,他引:1
将青蒿琥酯溶于苯二甲酸二甲酯,加适量氨酮制成皮肤擦剂。给兔脱毛后,皮肤涂抹此擦剂25mg/kg后,血药浓度达峰时间平均为2 h,峰浓度平均为1.80μg/ml。药物在兔体内平均驻留时间为3.54 h,清除半衰期约为2.46 h。给小鼠脱毛皮肤涂抹擦剂6.7,31.3和71.4 mg/kg,血药浓度在给药后0.5~4 h达高峰,峰浓度分别为0.82,2.05和7.11μg/ml,体内药物平均驻留时间为3.39,2.79及3.54 h,清除半衰期为2.35,1.93及2.45 h。可见,给兔及小鼠皮肤擦剂后,青蒿琥酯吸收良好,血药浓度维持时间较长。 相似文献
5.
Effect on management mortality of a deliberate policy of early operation on supratentorial aneurysms
Of 736 patients with intracranial aneurysms seen at the University of Alberta from 1968 to 1985, 437 were admitted on the day of or the day after subarachnoid hemorrhage (SAH) from a supratentorial aneurysm. Of these, 205 were managed from 1968 through 1977 and 232 were managed from 1978 through early 1985 after a policy of early aneurysm operation had been implemented. Postoperative and management mortality and morbidity rates were related to the grade of the patient at the time of admission and the time interval before operation. Overall management mortality (and postoperative mortality) rates for patients treated before 1978 were 47% (19%) for all grades, 17% (12%) for Grades 1 and 2, 51% (25%) for Grades 3 and 4, and 100% (100%) for Grade 5. Since 1978, mortality has been reduced to 38% (11%) for all grades, 10% (5%) for Grades 1 and 2, 39% (17%) for Grades 3 and 4, and 96% (60%) for Grade 5. Management mortality for patients operated on Day 0 to 3 was lower than for those operated later after SAH both before and after 1978. Postoperative mortality was lowered in all patients operated from 1978 to 1985 regardless of the interval from SAH to operation, and management mortality was reduced overall, as well as for patients operated on day 0 to 3, in those treated from 1978 to 1985. The authors conclude that a policy of early aneurysm operation has contributed to a reduction of both postoperative and management mortality. 相似文献
6.
7.
8.
9.
Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial 总被引:4,自引:0,他引:4
K C Petruk M West G Mohr B K Weir B G Benoit F Gentili L B Disney M I Khan M Grace R O Holness 《Journal of neurosurgery》1988,68(4):505-517
A multicenter, randomized placebo-controlled double-blind trial of nimodipine in poor-grade aneurysm patients was carried out in 17 Canadian hospitals. Of 188 patients enrolled in the trial, 32 were excluded for protocol violations and two were excluded due to statistical considerations, leaving 154 patients for valid outcome analysis. Nimodipine treatment was associated with a significantly better outcome (p less than 0.001): 21 (29.2%) of 72 nimodipine-treated patients had a good outcome at 3 months after subarachnoid hemorrhage (SAH) compared to eight (9.8%) of 82 placebo-treated patients. Delayed ischemic deficits from vasospasm alone were significantly less frequent in the nimodipine group (p less than 0.05) with permanent deficits occurring in five nimodipine-treated patients (6.9%) and in 22 placebo-treated patients (26.8%). Improvement in the good outcome rate and reduction in delayed ischemic deficits from vasospasm alone occurred in both Grade 3 and 4 patients, with no difference between nimodipine- and placebo-treated patients being found in Grade 5 patients. Repeat angiography after Day 4 was carried out in 124 patients. There was no significant difference in the incidence of moderate or severe diffuse spasm, which was seen in 64.3% of nimodipine-treated patients and 66.2% of placebo-treated patients. The authors conclude that nimodipine treatment in poor-grade patients with SAH results in an increase in the number of good outcomes and a reduction in the incidence of delayed neurological deterioration due to vasospasm. This effect occurs by a mechanism other than prevention of large-vessel spasm as visualized on angiography. 相似文献
10.